期刊文献+

基质金属蛋白酶2基因多态性与缺血性收缩性心衰预后相关 被引量:4

Polymorphisms of MMP-2 Gene are Associated with the Prognosis of Systolic Heart Failure
下载PDF
导出
摘要 目的基质金属蛋白酶家族(Matrix metalloproteinases,MMPs)是一组蛋白溶解酶系,在心肌细胞外基质降解过程中发挥重要作用。MMP-2作为家族中的重要成员,在心力衰竭心肌重构过程中起关键作用。我们推测MMP-2基因多态性可能会影响收缩性心衰的预后。方法对387位缺血性收缩性心衰患者进行随访,用限制性片段长度多态性的方法(restriction fragment length polymor- phism,RFLP)分析MMP-2基因的三个单核苷酸多态性(single nucleotide polymorphisms,SNPs)位点rs243864,rs243866,rs17859821。结果随访到335位患者,随访率86.6%。在随访期间(0~47个月,中位随访时间24个月),有72例(21.5%)患者死亡,56例(16.7%)患者因心衰再次入院,3例(0.9%)患者再次心肌梗塞,24例(7.2%)再次血运重建。1年、2年、3年的生存率分别是86%、79%、73%。MMP-2 rs17859821 A等位基因携带者全因死亡率、心源性死亡率、心衰死亡率和主要心脏不良事件率(major adverse cardiac event,MACE)均高于GG基因型者(OR=0.513,0.416,0.472,0.671;P=0.010,0.002,0.021,0.022)。使用Cox回归分析校正年龄、束支传导阻滞、LVEF和NYHA分级后,A等位基因携带者心源性死亡率和心衰死亡率仍显著或临界显著低于GG基因型者(OR= 0.475,0.518;P=0.010,0.050)。结论研究结果提示携带MMP-2 rs17859821 A等位基因的缺血性收缩性心衰患者预后较好。 Objective Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes responsible for myocardial extracellular protein degradation. MMP-2 is an important member of MMPs. MMP- 2 has been demonstrated to play a pivotal role in myocardial remodeling process that occurs in congestive heart failure (HF). We hypothesized MMP-2 genetic variations could influence the prognosis of systolic HF. Methods To test our hypothesis, we performed a follow-up study of 387 patients with systolic HF caused by myocardial infarction. Three single nueleotide polymorphisms (SNPs) of MMP-2 (rs243864, rs243866, rs17859821 ) were analyzed by restriction fragment length polymorphism (RFLP) methods. Results Three hundreds and thirty five patients (86. 6% ) were followed up. At follow up (0-47month, median 24 months), 72 patients (21.5%) died, 56 patients ( 16.7% ) were readmitted because of HF, 3 patients (0.9%) bad recurrent myocardial infarction, 24 patients (7. 2% ) had repeat revaseularization. One, two, and three year survival rates were 86% , 79% and 73%. All cause death rate, cardiac death rate, HF death rate and MACE rate were lower in MMP-2 rs17859821 A allele carriers than did GG genotype carriers ( OR = 0. 513,0. 416,0. 472, 0. 671 ;P =0. 010,0.002,0.021, 0. 022). After adjustment for age, bundle branch block, LVEF and NYHA grade by using cox regression analysis, cardiac death rate and HF death rate were still lower in MMP-2 A allele carriers than did GG genotype carriers( OR = 0. 475 and 0. 518 ;P = 0. 010,0. 050). Conclusion The findings of the present study suggest that MMP-2 rs17859821 A allele is associated with better prognosis of systolic heart failure in the northern Han Chinese population.
出处 《中国分子心脏病学杂志》 CAS 2009年第1期38-42,共5页 Molecular Cardiology of China
基金 中央级公益性科研专项基金(2006F007)
关键词 MMP-2 多态性 收缩性心力衰竭 预后 MMP-2 Polymorphism Systolic heart failure Prognosis
  • 相关文献

参考文献29

  • 1Sharon Ann Hunt,William T.Abraham,Marshall H.Chin,et al.ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult A Report of the American College of Cardiology/American Heart Association Task Force on Pracrice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).Circulation,2005,112(12):154-235.
  • 2Anselmi A,Suarez JA,Ansslmi G,et al.Primary cardiomyopathy in identical twins.Am J Cardiol,1975,35:97-102.
  • 3Littler WA.Twin studies in hypertrophic cardiomyopathy.Br Heart J,1972,34:1147-1151.
  • 4Indik JH,Smith DE,Sobonya RE,et al.Arrhythmogenic right ventrieular cardiomyopathy/dysplasia:a case report of identical twins with heart failure.Pacing Clin Electrophysiol,2002,25:1387-1390.
  • 5Morita H,Seidman J,Seidman CE.Genetic cauls of human heart failure.J Clin Invest,2005,115:518-526.
  • 6Nieminen MS.Bohm M.Cowie MR,et al.ESC Committee for Practice Guideline(CPG).Executive summary of the guidelines on the diagnosis and treatment of acute heart failure:the Task Force on Acute Heart Failure of the European Society of Cardiology.Eur Heart J,2005,26(4):384-416.
  • 7Noji Y,Shimim M,Ino H,et al.Increased circulating matrix metallopmteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction.Circ J,2004 Apr;68(4):355-360.
  • 8Banfi C,Cavalca V.Vegha F,et al.Neumhormonal activation is associated with increased levels of plasma matrix metallopreleinase-2 in human heart failure.Eur Heart J,2005 Mar;26(5):481-8.Epub 2004 Dec 17.
  • 9Tziakas DN,Chalikias GK,Papaioakeim M,et al.Comparison of levels of matrix metallopmteinsse-2 and-3 in patients with ischemic ardiomyopathy versus noniachemic cardiomyopathy.Am J Cardiol,2005,96(10):1449-1451.
  • 10George J.Patal S,Wexler D,et al.Circulating matrix melallopmteinase-2 but not matrix metallopmteinase-3,matrix metallopmteinase-9.or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.Am Beart J,2005,150(3):484-487.

同被引文献57

引证文献4

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部